New combo therapy shows promise for bile duct cancer
NCT ID NCT05771480
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy can help people with advanced biliary tract cancer (a type of bile duct cancer). About 142 participants will receive the combination, and researchers will track side effects, survival, and tumor shrinkage. The goal is to find a more effective first-line treatment for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (an immunotherapy drug) combined with gemcitabine-based chemotherapy
What this could lead to
If successful, this combination could become a new standard first-line treatment, helping people with advanced biliary tract cancer live longer and control their disease better.
What could go wrong
This is a single-arm, open-label study without a placebo group, so results may be less definitive. Side effects like severe immune reactions or infections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Mobile, Alabama, 36607, United States
-
Research Site
Orange, California, 92868, United States
-
Research Site
Washington D.C., District of Columbia, 20007, United States
-
Research Site
Portland, Oregon, 97213, United States
-
Research Site
Clichy, 92110, France
-
Research Site
Dijon, 21079, France
-
Research Site
Montpellier, 34090, France
-
Research Site
Villejuif, 94800, France
-
Research Site
Chemnitz, 09131, Germany
-
Research Site
Hanover, 30625, Germany
-
Research Site
Castelfranco Veneto, 31033, Italy
-
Research Site
Foggia, 71122, Italy
-
Research Site
Palermo, 90146, Italy
-
Research Site
Pisa, 56126, Italy
-
Research Site
Rozzano, 20089, Italy
-
Research Site
Chūōku, 104-0045, Japan
-
Research Site
Kanazawa, 920-8641, Japan
-
Research Site
Kashiwa, 227-8577, Japan
-
Research Site
Kyoto, 606-8507, Japan
-
Research Site
Osaka, 541-8567, Japan
-
Research Site
Sendai, 980-8574, Japan
-
Research Site
Ube, 755-8505, Japan
-
Research Site
Wakayama, 641-8509, Japan
-
Research Site
Yokohama, 241-8515, Japan
-
Research Site
Singapore, 169610, Singapore
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Madrid, 28027, Spain
-
Research Site
Madrid, 28040, Spain
-
Research Site
Madrid, 28041, Spain
-
Research Site
Pamplona, 31008, Spain
-
Research Site
Seville, 41013, Spain